Lesson plan
Nepadutant
Nepadutant (INN; development code MEN-11420) is a glycosylated bicyclic cyclohexapeptide drug which acts as a highly selective NK 2 receptor antagonist. It was developed by the Menarini Group and investigated for the treatment of functional gastrointestinal disorders and asthma but was never marketed.
Article summary
Nepadutant (INN; development code MEN-11420) is a glycosylated bicyclic cyclohexapeptide drug which acts as a highly selective NK 2 receptor antagonist. It was developed by the Menarini Group and investigated for the treatment of functional gastrointestinal disorders and asthma but was never marketed.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.